Building Molecular Diagnostic Models for Pancreatic Cystic Tumors Using Fluid Samples and Advanced DNA and Protein Testing

What this Trial Is About

This research aims to study patients with pancreatic cystic tumors to identify molecular diagnostic markers. It evaluates how cfDNA methylation sequencing and proteomic analysis of pancreatic cystic fluid can help distinguish between benign and malignant tumors, as well as mucinous and non-mucinous types. The study also seeks to correlate these molecular findings with pathological features and determine markers linked to the tumors degree of malignancy. Participants will provide samples of cystic fluid obtained after surgery. The study groups include mucinous tumor and non-mucinous tumor groups. Researchers will analyze cfDNA molecules and proteins in these fluid samples using sequencing and proteomic techniques. Multi-omics analysis will be performed to build a molecular diagnostic marker model to better identify and classify pancreatic cystic tumors. During the study, participants will undergo post-operative collection of cyst fluid specimens. Researchers will measure the types and concentrations of cfDNA and proteins in the fluid. They will also establish diagnostic models for pancreatic cystic tumors to differentiate mucinous from non-mucinous types and predict the progression from benign to malignant tumors. The study is observational and monitors molecular markers without administering treatments.

Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples